Study M010
Study name | Ji Y 2011 |
Title | Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics |
Overall design | For the current study, baseline metabolomic profiles of plasma samples were assayed in patients on SSRI treatment who were in the "remitters" category (remitter group; n = 20) and in the "nonremitters" category (nonremitter group; n = 20). Eight-week citalopram/escitalopram treatment outcome was determined using QIDS-C scores, with "remission" defined as QIDS-C <= 5 and "response" as QIDS-C reduction of >= 50%. MDD patients were selected for metabolomic profiling on the basis of their remission status at the week 8 clinic visit. A gas chromatography-mass spectrometry metabolomics platform was used to profile these 40 plasma samples. |
Study Type | Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 > 14 |
Sample size | 40 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; GC-MS: Agilent 6890 gas chromatograph (Santa Clara, CA) with Leco Pegasus IV time of flight mass spectrometer; |
PMID | |
DOI | |
Citation | Ji Y, Hebbring S, Zhu H, et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2011;89(1):97-104. |
Metabolite |
